Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers
October 20, 2022, 4:00 pm
Kite, a Gilead Company (Nasdaq: GILD) and Refuge Biotechnologies, Inc. ("Refuge"), today announced that Kite has entered into an exclusive, worldwide license agreement with Refuge, a synthetic biology company for cancer immunotherapy,
